Application of albumin-bound paclitaxel combined with AP regimen in invasive lobular carcinoma and its effect on FCN3,sRAGE and nectin-4
LI Jing
WANG Zhi-fei
YANG Geng-wu
LI Ying
LIU Zheng
Abstract：Objective To evaluate the application of albumin-bound paclitaxel combined with AP regimen in in-vasive lobular carcinoma and its effect on fibronectin-3(FCN3),soluble advanced glycation end products receptor(sRAGE),and nectin-4.Methods The clinical data of 200 patients with advanced invasive lobular carcinoma of the breast who were treated in Handan Central Hospital and the Fourth Hospital of Hebei Medical University from 2017 to 2020 were prospectively collected,and divided into control group and observation group by number table.The control group was treated with AP regimen and the observation group was treated with albumin-bound paclitaxel combined with AP regimen.The efficacy,quality of life,adverse reactions,FCN3,sRAGE and nectin-4 levels of the two groups were compared.The correlations between the levels of serum FCN3,sRAGE and nectin-4 in patients with different clinical pathological characteristics were analyzed.Results The clinical efficacy of the observation group was significantly higher than that of the control group(P＜0.05).The quality of life score of the observation group was significantly higher than that of the control group(P＜0.05).The incidence of adverse reactions in the observation group was significantly lower than that of the control group(P＜0.05).The levels of FCN3,sRAGE and nectin-4 in the two groups before treatment were not sig-nificantly different(P＞0.05).After treatment,the levels of FCN3,sRAGE and nectin-4 in the observation group were significantly better than those in the control group(P＜0.05).There was no significant difference in expression of serum FCN3,sRAGE or nectin-4,among patients with different age,pathological type,tumor diameter,progesterone receptor expression,proliferating cell nuclear antigen expression,or estrogen receptor expression(P＞0.05).There were signifi-cant differences in the expression of serum FCN3,sRAGE and nectin-4 among patients with different TNM stages,and lymph node metastasis(P＜0.05).Conclusion The combination therapy of albumin-bound paclitaxel with the AP reg-imen for the treatment of invasive lobular carcinoma has demonstrated precise efficacy,contributing to an improved quality of life for patients.This approach exhibits few adverse reactions,enhances serum factors,and positively influences prog-nosis.Therefore,it is worthy of widespread clinical application.
Keywords：albumin-bound paclitaxelAP regimeninvasivelobular carcinomaficolin 3soluble advanced glycation end product receptorconjugatein-4
Publication Date：2023-11-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 1390-1394 )